Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry
Open accessPublished version of a preprint
Abstract
Purpose: Recent transcriptomic analyses have identified four distinct molecular subtypes of colorectal cancer with evident clinical relevance. However, the requirement for sufficient quantities of bulk tumor and difficulties in obtaining high-quality genome-wide transcriptome data from formalin-fixed paraffin-embedded tissue are obstacles toward widespread adoption of this taxonomy. Here, we develop an immunohistochemistry-based classifier to validate the prognostic and predictive value of molecular colorectal cancer subtyping in a multicenter study. Experimental Design: Tissue microarrays from 1,076 patients with colorectal cancer from four different cohorts were stained for five markers (CDX2, FRMD6, HTR2B, ZEB1, and KER) by immunohistochemistry and assessed for microsatellite instability. An automated classification system was trained on one cohort using quantitative image analysis or semiquantitative pathologist scoring of the cores as input and applied to three independent clinical cohorts. Results: This classifier demonstrated 87% concordance with the gold-standard transcriptome-based classification. Application to three validation datasets confirmed the poor prognosis of the mesenchymal-like molecular colorectal cancer subtype. In addition, retrospective analysis demonstrated the benefit of adding cetuximab to bevacizumab and chemotherapy in patients with RAS wild-type metastatic cancers of the canonical epithelial-like subtypes. Conclusions: This study shows that a practical and robust immunohistochemical assay can be employed to identify molecular colorectal cancer subtypes and uncover subtype-specific therapeutic benefit. Finally, the described tool is available online for rapid classification of colorectal cancer samples, both in the format of an automated image analysis pipeline to score tumor core staining, and as a classifier based on semiquantitative pathology scoring. Clin Cancer Res; 23(2); 387–98. ©2016 AACR.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CMS4 tumors are characterized by an abundant expression of the master EMT transcription factor ZEB1 easily detectable by IHC.
“are characterized by an abundant expression of the master EMT transcription factor ZEB1 easily detectable by IHC (28).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [28]
IHC defines CMS4 as pMMR, CDX2-negative and FRMD6, HTR2B and ZEB1-positive tumors.
“IHC, CMS4 being defined as pMMR, CDX2-negative and FRMD6, HTR2B and ZEB1-positive tumors (28).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [28]
The citation lists haven’t been fetched yet
References 31 · Cited by 180
- Authors
- Trinh, A., Trumpi, K., De Sousa E Melo, F., Wang, X., de Jong, J. H., Fessler, E., Kuppen, P. J. K., Reimers, M. S., Swets, M., Koopman, M., Nagtegaal, I. D., Jansen, M., Hooijer, G. K. J., Offerhaus, G. J. A., Kranenburg, O., Punt, C. J., Medema, J. P., Markowetz, F., & Vermeulen, L.
- Affiliations
- University of Cambridge (GB)
- University Medical Center Utrecht (NL)
- 4Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
- City University of Hong Kong (HK)
- Amsterdam UMC Location University of Amsterdam (NL)
- Leiden University Medical Center (NL)
- 8Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Queen Mary University of London (GB)
- Corresponding author
- Vermeulen, Louis
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2017-01-15
- Volume
- 23
- Issue
- 2
- Pages
- 387-398
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2496518057
- Cited by
- 180
- References
- 31
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 18 · 2023: 13 · 2022: 17 · 2021: 25 · 2020: 25 · 2019: 16 · 2018: 20 · 2017: 17
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- green
- dspace.library.uu.nl
- Licence
- other-oa
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- KWF (UVA2011-4969 and UVA2014-7245)
- Worldwide Cancer Research (14-1164)
- Dutch Digestive Foundation (MLDS-CDG 14-03)
- European Research Council (ERG-StG 638193)
- CRUK (C14303/A17197 and A19274)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- colorectal cancer, molecular subtypes, CDX2, HTR2B, ZEB1, keratin, microsatellite instability, cetuximab, bevacizumab, prognostic factors, automated image analysis
- MeSH terms
- Cetuximab, CDX2 Transcription Factor, Zinc Finger E-box-Binding Homeobox 1, Adult, Aged, Aged, 80 and over, Clinical Trials as Topic, Cytoskeletal Proteins, Female, Humans, Immunohistochemistry, Male, Membrane Proteins, Middle Aged, Prognosis, Proteoglycans, Biomarkers, Tumor, Colorectal Neoplasms, Gene Expression Profiling, Microsatellite Instability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review